

Patient Name: 박세영
Gender: M
Sample ID: N25-285

Primary Tumor Site: Lung
Collection Date: 2025.10.21

Sample Cancer Type: Lung Cancer

Table of Contents	Page	Report Highlights
Variant Details	2	1 Relevant Biomarkers
Biomarker Descriptions	2	0 Therapies Available
Relevant Therapy Summary	6	1 Clinical Trials

Relevant Lung Cancer Findings

Gene	Finding	Gene	Finding
ALK	None detected	NTRK1	None detected
BRAF	None detected	NTRK2	None detected
EGFR	None detected	NTRK3	None detected
ERBB2	None detected	RET	None detected
KRAS	None detected	ROS1	None detected
MET	None detected		

Genomic Alteration	Finding
Tumor Mutational Burden	8.02 Mut/Mb measured

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IIC	BRIP1 p.(E879Dfs*5) c.2637_2637delAinsCG BRCA1 interacting protein C-terminal helicase 1 Allele Frequency: 2.38% Locus: chr17:59763465 Transcript: NM_032043.3	None*	None*	1

* Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO
* Public data sources included in prognostic and diagnostic significance: NCCN, ESMO
Line of therapy: I: First-line therapy, II+: Other line of therapy
Tier Reference: Li et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 Jan;19(1):4-23.

Prevalent cancer biomarkers without relevant evidence based on included data sources

APC p.(E1552Gfs*6) c.4655_4656delAG, APC p.(S1758Ffs*11) c.5268_5270delTTCinsGTCT, FBXW7 p.(R505G) c.1513C>G, Microsatellite stable, NFE2L2 p.(E82G) c.245A>G, TP53 p.(V157F) c.469G>T, Tumor Mutational Burden

Variant Details

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect
BRIP1	p.(E879Dfs*5)	c.2637_2637delAinsCG	.	chr17:59763465	2.38%	NM_032043.3	frameshift Block Substitution
APC	p.(E1552Gfs*6)	c.4655_4656delAG	.	chr5:112175943	75.00%	NM_000038.6	frameshift Deletion
APC	p.(S1758Ffs*11)	c.5268_5270delTTCins GTCT	.	chr5:112176559	1.83%	NM_000038.6	frameshift Block Substitution
FBXW7	p.(R505G)	c.1513C>G	COSM99603	chr4:153247289	66.40%	NM_033632.3	missense
NFE2L2	p.(E82G)	c.245A>G	COSM132853	chr2:178098800	46.00%	NM_006164.5	missense
TP53	p.(V157F)	c.469G>T	COSM10670	chr17:7578461	67.92%	NM_000546.6	missense
COL11A1	p.(R1076C)	c.3226C>T	.	chr1:103412455	67.83%	NM_001854.4	missense
OR2W3	p.(H131P)	c.392A>C	.	chr1:248059280	32.42%	NM_001001957.2	missense
FAT1	p.(N143S)	c.428A>G	.	chr4:187630554	15.96%	NM_005245.4	missense
CD274	p.(M10K)	c.29T>A	.	chr9:5456142	15.21%	NM_014143.4	missense
OR4M2	p.(C169S)	c.506G>C	.	chr15:22369081	20.36%	NM_001004719.2	missense
NCOR1	p.(R2250T)	c.6749G>C	.	chr17:15942953	86.00%	NM_006311.4	missense

Biomarker Descriptions

BRIP1 p.(E879Dfs*5) c.2637_2637delAinsCG

BRCA1 interacting protein C-terminal helicase 1

Background: The BRIP1 gene encodes the BRCA1 interacting protein C-terminal helicase 1 and is a member of the RecQ DEAH helicase family that plays a role in homologous recombination repair (HRR) of double-stranded breaks (DSBs) in DNA¹. BRIP1 interacts directly with BRCA1 through the BRCT domain and controls BRCA1-dependent DNA repair and the DNA damage-induced G2-M checkpoint control². BRIP1 is a tumor suppressor gene. Loss of function mutations in BRIP1 are implicated in the BRCAness phenotype, characterized by a defect in HRR, mimicking BRCA1 or BRCA2 loss^{3,4}. Germline aberrations in BRIP1 are associated with inherited disorders such as Fanconi anemia (FA)⁵. Specifically, BRIP1 was shown to be biallelically inactivated in FA patients and is also considered a high-risk gene for familial late-onset ovarian cancer^{5,6}. BRIP1 germline mutations confer ~ 10% cumulative risk of ovarian cancer and are associated with an increased risk of colorectal cancer^{1,7}.

Alterations and prevalence: Somatic mutations in BRIP1 are observed in up to 8% of uterine corpus endometrial carcinoma, 5% of skin cutaneous melanoma, and 4% of bladder urothelial carcinoma^{8,9}.

Potential relevance: The PARP inhibitor, olaparib¹⁰ is approved (2020) for metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious, germline or somatic mutations in HRR genes that includes BRIP1. Consistent with other genes associated with the BRCAness phenotype, BRIP1 mutations may aid in selecting patients likely to respond to PARP inhibitors or platinum therapy^{3,11}. In 2022, the FDA granted fast track designation to the small molecule inhibitor, pidnarulex¹², for BRCA1/2, PALB2, or other homologous recombination deficiency (HRD) mutations in breast and ovarian cancers.

APC p.(E1552Gfs*6) c.4655_4656delAG, APC p.(S1758Ffs*11) c.5268_5270delTTCinsGTCT

APC, WNT signaling pathway regulator

Background: The APC gene encodes the adenomatous polyposis coli tumor suppressor protein that plays a crucial role in regulating the β -catenin/WNT signaling pathway which is involved in cell migration, adhesion, proliferation, and differentiation⁷⁴. APC is an antagonist of WNT signaling as it targets β -catenin for proteasomal degradation^{75,76}. Germline mutations in APC are predominantly inactivating and result in an autosomal dominant predisposition for familial adenomatous polyposis (FAP) which is characterized by

Biomarker Descriptions (continued)

numerous polyps in the intestine^{74,77}. Acquiring a somatic mutation in APC is considered to be an early and possibly initiating event in colorectal cancer⁷⁸.

Alterations and prevalence: Somatic mutations in APC are observed in up to 65% of colorectal cancer, and in up to 15% of stomach adenocarcinoma and uterine corpus endometrial carcinoma^{8,9,79}. In colorectal cancer, ~60% of somatic APC mutations have been reported to occur in a mutation cluster region (MCR) resulting in C-terminal protein truncation and APC inactivation^{80,81}.

Potential relevance: Currently, no therapies are approved for APC aberrations.

FBXW7 p.(R505G) c.1513C>G

F-box and WD repeat domain containing 7

Background: The FBXW7 gene encodes a member of the F-box protein family that functions as the substrate recognition component of the SCF complex, which is responsible for protein ubiquitination and subsequent degradation by the proteasome⁴¹. FBXW7 is a tumor suppressor gene that plays a crucial role in the degradation and turnover of various proto-oncogenes. Aberrations such as mutations or deletions that alter the tumor suppression function can lead to the deregulation of downstream genes, including MYC, MTOR, and NOTCH1, thereby promoting cell proliferation and survival^{41,42,43,44,45,46,47}.

Alterations and prevalence: Mutations in FBXW7 occur at high frequencies in various malignancies, including 40% of uterine carcinoma and 10-15% of stomach, bladder, cervical, and colorectal cancers^{8,9,48,49,50}.

Potential relevance: The FDA has granted fast track designation (2024) to the small molecule PKMYT1 inhibitor, lunresertib⁵¹, in combination with camonsertib for the treatment of adult patients with FBXW7 mutated endometrial cancer and platinum resistant ovarian cancer. Missense mutations in FBXW7 are associated with poor prognosis and worse overall survival (OS) in comparison to FBXW7 wild-type metastatic colorectal cancer⁴⁸. In a clinical case report, a patient with FBXW7 R465H-mutated, EGFR/ALK-wildtype lung adenocarcinoma demonstrated tumor shrinkage after treatment with the mTOR inhibitor temsirolimus. In a phase I clinical trial of sirolimus, one hepatocellular fibrolamellar carcinoma patient with the FBXW7 E192A mutation demonstrated stable disease for over 6 months⁴⁷.

Microsatellite stable

Background: Microsatellites are short tandem repeats (STR) of 1 to 6 bases of DNA between 5 to 50 repeat units in length. There are approximately 0.5 million STRs that occupy 3% of the human genome⁵². Microsatellite instability (MSI) is defined as a change in the length of a microsatellite in a tumor as compared to normal tissue^{53,54}. MSI is closely tied to the status of the mismatch repair (MMR) genes. In humans, the core MMR genes include MLH1, MSH2, MSH6, and PMS2⁵⁵. Mutations and loss of expression in MMR genes, known as defective MMR (dMMR), lead to MSI. In contrast, when MMR genes lack alterations, they are referred to as MMR proficient (pMMR). Consensus criteria were first described in 1998 and defined MSI-high (MSI-H) as instability in two or more of the following five markers: BAT25, BAT26, D5S346, D2S123, and D17S250⁵⁶. Tumors with instability in one of the five markers were defined as MSI-low (MSI-L) whereas, those with instability in zero markers were defined as MS-stable (MSS)⁵⁶. Tumors classified as MSI-L are often phenotypically indistinguishable from MSS tumors and tend to be grouped with MSS^{57,58,59,60,61}. MSI-H is a hallmark of Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, which is caused by germline mutations in the MMR genes⁵⁴. LS is associated with an increased risk of developing colorectal cancer, as well as other cancers, including endometrial and stomach cancer^{53,54,58,62}.

Alterations and prevalence: The MSI-H phenotype is observed in 30% of uterine corpus endothelial carcinoma, 20% of stomach adenocarcinoma, 15-20% of colon adenocarcinoma, and 5-10% of rectal adenocarcinoma^{53,54,63,64}. MSI-H is also observed in 5% of adrenal cortical carcinoma and at lower frequencies in other cancers such as esophageal, liver, and ovarian cancers^{63,64}.

Potential relevance: Anti-PD-1 immune checkpoint inhibitors including pembrolizumab⁶⁵ (2014) and nivolumab⁶⁶ (2015) are approved for patients with MSI-H or dMMR colorectal cancer who have progressed following chemotherapy. Pembrolizumab⁶⁵ is also approved as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR with disease progression on prior therapy who are not candidates for surgery or radiation. Importantly, pembrolizumab is approved for the treatment of MSI-H or dMMR solid tumors that have progressed following treatment, with no alternative option and is the first anti-PD-1 inhibitor to be approved with a tumor agnostic indication⁶⁵. Dostarlimab⁶⁷ (2021) is also approved for dMMR recurrent or advanced endometrial carcinoma or solid tumors that have progressed on prior treatment and is recommended as a subsequent therapy option in dMMR/MSI-H advanced or metastatic colon or rectal cancer^{59,68}. The cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, ipilimumab⁶⁹ (2011), is approved alone or in combination with nivolumab in MSI-H or dMMR colorectal cancer that has progressed following treatment with chemotherapy. MSI-H may confer a favorable prognosis in colorectal cancer although outcomes vary depending on stage and tumor location^{59,70,71}. Specifically, MSI-H is a strong prognostic indicator of better overall survival (OS) and relapse free survival (RFS) in stage II as compared to stage III colorectal cancer patients⁷¹. The majority of patients with tumors classified as either MSS or pMMR do not benefit from treatment with single-agent immune checkpoint inhibitors as compared to those

Biomarker Descriptions (continued)

with MSI-H tumors^{72,73}. However, checkpoint blockade with the addition of chemotherapy or targeted therapies have demonstrated response in MSS or pMMR cancers^{72,73}.

NFE2L2 p.(E82G) c.245A>G

nuclear factor, erythroid 2 like 2

Background: The NFE2L2 gene encodes the nuclear factor, erythroid 2 like 2 transcription factor, a member of the basic leucine zipper protein family¹³. NFE2L2, also known as NRF2, is a proto-oncogene that activates transcription of genes with antioxidant response elements (ARE)³⁷. NFE2L2 targets include genes involved in antioxidant response, drug metabolism, DNA repair, autophagy, cell survival, and proliferation^{37,38}. NFE2L2 is negatively regulated by KEAP1, a Cul3 adaptor protein, that ubiquitinates NFE2L2³⁸.

Alterations and prevalence: Recurrent somatic mutations in NFE2L2 are observed in 14% of lung squamous cell carcinoma, 9% of esophageal adenocarcinoma, and 5% of head and neck squamous cell carcinoma^{8,9}. Deletion of NFE2L2 exon 2 or exon 2 and 3 result in an isoform leading to the lack of the KEAP1 interacting domain, NFE2L2 stabilization, and expression of NFE2L2 targets such as HMOX1, G6PD, PDGFC, FGF2, and NQO1^{37,39}.

Potential relevance: Currently, no therapies are approved for NFE2L2 aberrations. The FDA has granted fast track designation (2022) to the mTORC 1/2 inhibitor, sapanisertib (CB-228)⁴⁰, for patients with NFE2L2 mutated, unresectable or metastatic squamous non-small cell lung cancer (NSCLC) who have received prior platinum-based chemotherapy and immune checkpoint inhibitor therapy.

TP53 p.(V157F) c.469G>T

tumor protein p53

Background: The TP53 gene encodes the tumor suppressor protein p53, which binds to DNA and activates transcription in response to diverse cellular stresses to induce cell cycle arrest, apoptosis, or DNA repair¹³. In unstressed cells, TP53 is kept inactive by targeted degradation via MDM2, a substrate recognition factor for ubiquitin-dependent proteolysis¹⁴. Alterations in TP53 are required for oncogenesis as they result in loss of protein function and gain of transforming potential¹⁵. Germline mutations in TP53 are the underlying cause of Li-Fraumeni syndrome, a complex hereditary cancer predisposition disorder associated with early-onset cancers^{16,17}.

Alterations and prevalence: TP53 is the most frequently mutated gene in the cancer genome with approximately half of all cancers experiencing TP53 mutations. Ovarian, head and neck, esophageal, and lung squamous cancers have particularly high TP53 mutation rates (60-90%)^{8,9,18,19,20,21}. Approximately two-thirds of TP53 mutations are missense mutations and several recurrent missense mutations are common, including substitutions at codons R158, R175, Y220, R248, R273, and R282^{8,9}. Invariably, recurrent missense mutations in TP53 inactivate its ability to bind DNA and activate transcription of target genes^{22,23,24,25}. Alterations in TP53 are also observed in pediatric cancers^{8,9}. Somatic mutations are observed in 53% of non-Hodgkin lymphoma, 24% of soft tissue sarcoma, 19% of glioma, 13% of bone cancer, 9% of B-lymphoblastic leukemia/lymphoma, 4% of embryonal tumors, 3% of Wilms tumor and leukemia, 2% of T-lymphoblastic leukemia/lymphoma, and less than 1% of peripheral nervous system cancers (5 in 1158 cases)^{8,9}. Biallelic loss of TP53 is observed in 10% of bone cancer, 2% of Wilms tumor, and less than 1% of B-lymphoblastic leukemia/lymphoma (2 in 731 cases) and leukemia (1 in 250 cases)^{8,9}.

Potential relevance: The small molecule p53 reactivator, PC14586²⁶ (2020), received a fast track designation by the FDA for advanced tumors harboring a TP53 Y220C mutation. In addition to investigational therapies aimed at restoring wild-type TP53 activity, compounds that induce synthetic lethality are also under clinical evaluation^{27,28}. TP53 mutation are a diagnostic marker of SHH-activated, TP53-mutant medulloblastoma²⁹. TP53 mutations confer poor prognosis and poor risk in multiple blood cancers including AML, MDS, myeloproliferative neoplasms (MPN), and chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL)^{30,31,32,33,34}. In mantle cell lymphoma, TP53 mutations are associated with poor prognosis when treated with conventional therapy including hematopoietic cell transplant³⁵. Mono- and bi-allelic mutations in TP53 confer unique characteristics in MDS, with multi-hit patients also experiencing associations with complex karyotype, few co-occurring mutations, and high-risk disease presentation as well as predicted death and leukemic transformation independent of the IPSS-R staging system³⁶.

Genes Assayed

Genes Assayed for the Detection of DNA Sequence Variants

ABL1, ABL2, ACVR1, AKT1, AKT2, AKT3, ALK, AR, ARAF, ATP1A1, AURKA, AURKB, AURKC, AXL, BCL2, BCL2L12, BCL6, BCR, BMP5, BRAF, BTK, CACNA1D, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD79B, CDK4, CDK6, CHD4, CSF1R, CTNNB1, CUL1, CYSLTR2, DDR2, DGCR8, DROSHA, E2F1, EGFR, EIF1AX, EPAS1, ERBB2, ERBB3, ERBB4, ESR1, EZH2, FAM135B, FGF7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FOXL2, FOXO1, GATA2, GLI1, GNA11, GNAQ, GNAS, HIF1A, HRAS, IDH1, IDH2, IKBKB, IL6ST, IL7R, IRF4, IRS4, KCNJ5, KDR, KIT, KLF4, KLF5, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAPK1, MAX, MDM4, MECOM, MED12, MEF2B, MET, MITF, MPL, MTOR, MYC, MYCN, MYD88, MYO10, NFE2L2, NRAS, NSD2, NT5C2, NTRK1, NTRK2, NTRK3, NUP93, PAX5, PCBP1, PDGFRA, PDGFRB, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R2, PIM1, PLCG1, PPP2R1A, PPP6C, PRKACA, PTPN11, PTPRD, PXDNL, RAC1, RAF1, RARA, RET, RGS7, RHEB, RHOA, RICTOR, RIT1, ROS1, RPL10, SETBP1, SF3B1, SIX1, SIX2, SLC01B3, SMC1A, SMO, SNCAIP, SOS1, SOX2, SPOP, SRC, SRSF2, STAT3, STAT5B, STAT6, TAF1, TERT, TGFB1, TOP1, TOP2A, TPMT, TRRAP, TSHR, U2AF1, USP8, WAS, XPO1, ZNF217, ZNF429

Genes Assayed for the Detection of Copy Number Variations

ABCB1, ABL1, ABL2, ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AKT1, AKT2, AKT3, ALK, AMER1, APC, AR, ARAF, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKC, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BCL2, BCL2L12, BCL6, BCOR, BLM, BMPR2, BRAF, BRCA1, BRCA2, BRIP1, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHD4, CHEK1, CHEK2, CIC, CREBBP, CSMD3, CTCF, CTLA4, CTNND2, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, DAXX, DDR1, DDR2, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, EGFR, EIF1AX, ELF3, EMSY, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERBB2, ERBB3, ERBB4, ERCC2, ERCC4, ERFF1, ESR1, ETV6, EZH2, FAM135B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAT1, FBXW7, FGF19, FGF23, FGF3, FGF4, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FUBP1, FYN, GATA2, GATA3, GLI3, GNA13, GNAS, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, IDH2, IGF1R, IKBKB, IL7R, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KDR, KEAP1, KIT, KLF5, KMT2A, KMT2B, KMT2C, KMT2D, KRAS, LARP4B, LATS1, LATS2, MAGOH, MAP2K1, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK1, MAPK8, MAX, MCL1, MDM2, MDM4, MECOM, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLH3, MPL, MRE11, MSH2, MSH3, MSH6, MTAP, MTOR, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NCOR1, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NRAS, NTRK1, NTRK3, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PCBP1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDIA3, PGD, PHF6, PIK3C2B, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PIM1, PLCG1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PRDM9, PRKACA, PRKAR1A, PTCH1, PTEN, PTPN11, PTPRT, PXDNL, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RASA1, RASA2, RB1, RBM10, RECQL4, RET, RHEB, RICTOR, RIT1, RNASEH2A, RNASEH2B, RNF43, ROS1, RPA1, RPS6KB1, RPTOR, RUNX1, SDHA, SDHB, SDHD, SETBP1, SETD2, SF3B1, SLC01B3, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SMC1A, SMO, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STAT6, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TERT, TET2, TGFB2, TNFAIP3, TNFRSF14, TOP1, TP53, TP63, TPMT, TPP2, TSC1, TSC2, U2AF1, USP8, USP9X, VHL, WT1, XPO1, XRCC2, XRCC3, YAP1, YES1, ZFXH3, ZMYM3, ZNF217, ZNF429, ZRSR2

Genes Assayed for the Detection of Fusions

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSP02, RSP03, TERT

Genes Assayed with Full Exon Coverage

ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AMER1, APC, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AXIN1, AXIN2, B2M, BAP1, BARD1, BCOR, BLM, BMPR2, BRCA1, BRCA2, BRIP1, CALR, CASP8, CBFB, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHEK1, CHEK2, CIC, CIITA, CREBBP, CSMD3, CTCF, CTLA4, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, CYP2D6, DAXX, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, ELF3, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERCC2, ERCC4, ERCC5, ERFF1, ETV6, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FBXW7, FUBP1, GATA3, GNA13, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, ID3, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KEAP1, KLHL13, KMT2A, KMT2B, KMT2C, KMT2D, LARP4B, LATS1, LATS2, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK8, MEN1, MGA, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MTAP, MTUS2, MUTYH, NBN, NCOR1, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PDCD1, PDCD1LG2, PDIA3, PGD, PHF6, PIK3R1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R2A, PRDM1, PRDM9, PRKAR1A, PSMB10, PSMB8, PSMB9, PTCH1, PTEN, PTPRT, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RASA1, RASA2, RB1, RBM10, RECQL4, RNASEH2A, RNASEH2B, RNASEH2C, RNF43, RPA1, RPL22, RPL5, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SOCS1, SOX9, SPEN, STAG2, STAT1, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TET2, TGFB2, TMEM132D, TNFAIP3, TNFRSF14, TP53, TP63, TPP2, TSC1, TSC2, UGT1A1, USP9X, VHL, WT1, XRCC2, XRCC3, ZBTB20, ZFXH3, ZMYM3, ZRSR2

Relevant Therapy Summary

☒ In this cancer type ☐ In other cancer type ☒ In this cancer type and other cancer types ☒ No evidence

BRIP1 p.(E879Dfs*5) c.2637_2637delAinsCG

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
talazoparib	×	×	×	×	<input checked="" type="radio"/> (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

HRR Details

Gene/Genomic Alteration	Finding
Not Detected	Not Applicable

Homologous recombination repair (HRR) genes were defined from published evidence in relevant therapies, clinical guidelines, as well as clinical trials, and include - BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L.

Thermo Fisher Scientific's Ion Torrent OncoPrint Reporter software was used in generation of this report. Software was developed and designed internally by Thermo Fisher Scientific. The analysis was based on OncoPrint Reporter (6.1.1 data version 2025.10(006)). The data presented here are from a curated knowledge base of publicly available information, but may not be exhaustive. FDA information was sourced from www.fda.gov and is current as of 2025-09-17. NCCN information was sourced from www.nccn.org and is current as of 2025-09-02. EMA information was sourced from www.ema.europa.eu and is current as of 2025-09-17. ESMO information was sourced from www.esmo.org and is current as of 2025-09-02. Clinical Trials information is current as of 2025-09-02. For the most up-to-date information regarding a particular trial, search www.clinicaltrials.gov by NCT ID or search local clinical trials authority website by local identifier listed in 'Other identifiers.' Variants are reported according to HGVS nomenclature and classified following AMP/ASCO/CAP guidelines (Li et al. 2017). Based on the data sources selected, variants, therapies, and trials listed in this report are listed in order of potential clinical significance but not for predicted efficacy of the therapies.

References

1. Ali et al. BRIP-1 germline mutation and its role in colon cancer: presentation of two case reports and review of literature. *BMC Med Genet.* 2019 May 7;20(1):75. PMID: 31064327
2. Daino et al. Loss of the BRCA1-interacting helicase BRIP1 results in abnormal mammary acinar morphogenesis. *PLoS ONE.* 2013;8(9):e74013. PMID: 24040146
3. Lim et al. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. *Endocr. Relat. Cancer.* 2016 Jun;23(6):R267-85. PMID: 27226207
4. Lord et al. BRCAness revisited. *Nat. Rev. Cancer.* 2016 Feb;16(2):110-20. PMID: 26775620
5. Taniguchi et al. Molecular pathogenesis of Fanconi anemia: recent progress. *Blood.* 2006 Jun 1;107(11):4223-33. PMID: 16493006
6. Weber-Lassalle et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. *Breast Cancer Res.* 2018 Jan 24;20(1):7. PMID: 29368626
7. Ramus et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *J. Natl. Cancer Inst.* 2015 Nov;107(11). PMID: 26315354
8. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
9. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf
11. Pennington et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. *Clin. Cancer Res.* 2014 Feb 1;20(3):764-75. PMID: 24240112
12. <https://www.senhwabio.com/en/news/20220125>
13. O'Leary et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* 2016 Jan 4;44(D1):D733-45. PMID: 26553804
14. Nag et al. The MDM2-p53 pathway revisited. *J Biomed Res.* 2013 Jul;27(4):254-71. PMID: 23885265
15. Muller et al. Mutant p53 in cancer: new functions and therapeutic opportunities. *Cancer Cell.* 2014 Mar 17;25(3):304-17. PMID: 24651012
16. Olivier et al. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol.* 2010 Jan;2(1):a001008. PMID: 20182602
17. Guha et al. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. *Cold Spring Harb Perspect Med.* 2017 Apr 3;7(4). PMID: 28270529
18. Peter et al. Comprehensive genomic characterization of squamous cell lung cancers. *Nature.* 2012 Sep 27;489(7417):519-25. PMID: 22960745
19. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature.* 2015 Jan 29;517(7536):576-82. PMID: 25631445
20. Campbell et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. *Nat. Genet.* 2016 Jun;48(6):607-16. PMID: 27158780
21. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. *Nature.* 2017 Jan 12;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4. PMID: 28052061
22. Olivier et al. The IARC TP53 database: new online mutation analysis and recommendations to users. *Hum. Mutat.* 2002 Jun;19(6):607-14. PMID: 12007217
23. Rivlin et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. *Genes Cancer.* 2011 Apr;2(4):466-74. PMID: 21779514
24. Petitjean et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. *Oncogene.* 2007 Apr 2;26(15):2157-65. PMID: 17401424
25. Soussi et al. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. *Hum. Mutat.* 2014 Jun;35(6):766-78. PMID: 24729566
26. <https://www.globenewswire.com/news-release/2020/10/13/2107498/0/en/PMV-Pharma-Granted-FDA-Fast-Track-Designation-of-PC14586-for-the-Treatment-of-Advanced-Cancer-Patients-that-have-Tumors-with-a-p53-Y220C-Mutation.html>
27. Parrales et al. Targeting Oncogenic Mutant p53 for Cancer Therapy. *Front Oncol.* 2015 Dec 21;5:288. doi: 10.3389/fonc.2015.00288. eCollection 2015. PMID: 26732534
28. Zhao et al. Molecularly targeted therapies for p53-mutant cancers. *Cell. Mol. Life Sci.* 2017 Nov;74(22):4171-4187. PMID: 28643165

References (continued)

29. Louis et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021 Aug 2;23(8):1231-1251. PMID: 34185076
30. Döhner et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood.* 2022 Sep 22;140(12):1345-1377. PMID: 35797463
31. NCCN Guidelines® - NCCN-Myelodysplastic Syndromes [Version 2.2025]
32. NCCN Guidelines® - NCCN-Myeloproliferative Neoplasms [Version 2.2025]
33. NCCN Guidelines® - NCCN-Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Version 3.2025]
34. NCCN Guidelines® - NCCN-Acute Lymphoblastic Leukemia [Version 2.2025]
35. NCCN Guidelines® - NCCN-B-Cell Lymphomas [Version 3.2025]
36. Bernard et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nat. Med.* 2020 Aug 3. PMID: 32747829
37. Rojo et al. NRF2 and the Hallmarks of Cancer. *Cancer Cell.* 2018 Jul 9;34(1):21-43. PMID: 29731393
38. Suzuki et al. Toward clinical application of the Keap1-Nrf2 pathway. *Trends Pharmacol. Sci.* 2013 Jun;34(6):340-6. PMID: 23664668
39. Goldstein et al. Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers. *Cell Rep.* 2016 Sep 6;16(10):2605-2617. PMID: 27568559
40. <https://ir.calithera.com/news-releases/news-release-details/calithera-receives-fda-fast-track-designation-sapanisertib>
41. Yeh et al. FBXW7: a critical tumor suppressor of human cancers. *Mol Cancer.* 2018 Aug 7;17(1):115. doi: 10.1186/s12943-018-0857-2. PMID: 30086763
42. Wang et al. Tumor suppressor functions of FBW7 in cancer development and progression. *FEBS Lett.* 2012 May 21;586(10):1409-18. PMID: 22673505
43. Uhlén et al. Proteomics. Tissue-based map of the human proteome. *Science.* 2015 Jan 23;347(6220):1260419. doi: 10.1126/science.1260419. PMID: 25613900
44. Yada et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. *EMBO J.* 2004 May 19;23(10):2116-25. PMID: 15103331
45. Hori et al. Notch signaling at a glance. *J. Cell. Sci.* 2013 May 15;126(Pt 10):2135-40. PMID: 23729744
46. Aydin et al. FBXW7 mutations in melanoma and a new therapeutic paradigm. *J. Natl. Cancer Inst.* 2014 Jun;106(6):dju107. PMID: 24838835
47. Jardim et al. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. *PLoS ONE.* 2014;9(2):e89388. PMID: 24586741
48. Korphaisarn et al. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. *Oncotarget.* 2017 Jun 13;8(24):39268-39279. PMID: 28424412
49. Donna et al. Comprehensive molecular characterization of human colon and rectal cancer. *Nature.* 2012 Jul 18;487(7407):330-7. PMID: 22810696
50. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature.* 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29. PMID: 24476821
51. <https://ir.reparerx.com/news-releases/news-release-details/repere-therapeutics-announces-fast-track-designation-granted-fda>
52. Lander et al. Initial sequencing and analysis of the human genome. *Nature.* 2001 Feb 15;409(6822):860-921. PMID: 11237011
53. Baudrin et al. Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer. *Front Oncol.* 2018 Dec 12;8:621. doi: 10.3389/fonc.2018.00621. eCollection 2018. PMID: 30631754
54. Nojadeh et al. Microsatellite instability in colorectal cancer. *EXCLI J.* 2018;17:159-168. PMID: 29743854
55. Saeed et al. Microsatellites in Pursuit of Microbial Genome Evolution. *Front Microbiol.* 2016 Jan 5;6:1462. doi: 10.3389/fmicb.2015.01462. eCollection 2015. PMID: 26779133
56. Boland et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* 1998 Nov 15;58(22):5248-57. PMID: 9823339
57. Halford et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. *Cancer Res.* 2002 Jan 1;62(1):53-7. PMID: 11782358
58. Imai et al. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. *Carcinogenesis.* 2008 Apr;29(4):673-80. PMID: 17942460

References (continued)

59. NCCN Guidelines® - NCCN-Colon Cancer [Version 4.2025]
60. Pawlik et al. Colorectal carcinogenesis: MSI-H versus MSI-L. *Dis. Markers*. 2004;20(4-5):199-206. PMID: 15528785
61. Lee et al. Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer. *Medicine (Baltimore)*. 2015 Dec;94(50):e22260. PMID: 26683947
62. Latham et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *J. Clin. Oncol.* 2019 Feb 1;37(4):286-295. PMID: 30376427
63. Cortes-Ciriano et al. A molecular portrait of microsatellite instability across multiple cancers. *Nat Commun.* 2017 Jun 6;8:15180. doi: 10.1038/ncomms15180. PMID: 28585546
64. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precis Oncol.* 2017;2017. PMID: 29850653
65. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf
66. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s131lbl.pdf
67. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s009lbl.pdf
68. NCCN Guidelines® - NCCN-Rectal Cancer [Version 3.2025]
69. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s136lbl.pdf
70. Ribic et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N. Engl. J. Med.* 2003 Jul 17;349(3):247-57. PMID: 12867608
71. Klingbiel et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. *Ann. Oncol.* 2015 Jan;26(1):126-32. PMID: 25361982
72. Hermel et al. The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer. *J Pers Med.* 2019 Jan 16;9(1). PMID: 30654522
73. Ciardiello et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer Treat. Rev.* 2019 Jun;76:22-32. PMID: 31079031
74. Wang et al. Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. *Cell. Physiol. Biochem.* 2018;51(6):2647-2693. PMID: 30562755
75. Stamos et al. The β -catenin destruction complex. *Cold Spring Harb Perspect Biol.* 2013 Jan 1;5(1):a007898. PMID: 23169527
76. Minde et al. Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?. *Mol Cancer.* 2011 Aug 22;10:101. doi: 10.1186/1476-4598-10-101. PMID: 21859464
77. Aoki et al. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. *J. Cell. Sci.* 2007 Oct 1;120(Pt 19):3327-35. PMID: 17881494
78. Miyoshi et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. *Hum. Mol. Genet.* 1992 Jul;1(4):229-33. PMID: 1338904
79. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature.* 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23. PMID: 25079317
80. Rowan et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". *Proc. Natl. Acad. Sci. U.S.A.* 2000 Mar 28;97(7):3352-7. PMID: 10737795
81. Laurent-Puig et al. APC gene: database of germline and somatic mutations in human tumors and cell lines. *Nucleic Acids Res.* 1998 Jan 1;26(1):269-70. PMID: 9399850